RxDoctor Payments Data

Emily Sparks

Optometrist · Scranton, PANPI 1164872727

Payments from drug & device makers

$2,341in general payments, 2019–2025

Across 82 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$338
  • AbbVie$337
  • Oyster Point Pharma, Inc.$276
  • Sun Pharmaceutical Industries Inc.$214
  • Novartis$187
  • Bausch & Lomb Americas Inc.$163
  • plus $827 from 10 others

What the payments were for

  • Food & beverage$2,32299%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,341 in reported general payments places this provider in the 80th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$106,802
Medicare patients
704
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$64,692
XiidraLifitegrast19$25,898
Cyclosporine19$6,830
Latanoprost93$1,498
Prednisolone Acetate34$1,281
Timolol Maleate23$1,156
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha79$837
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat39$709
Epinastine Hcl13$550
ErythromycinErythromycin Base36$392
Brimonidine Tartrate26$320
Cephalexin14$305
Ofloxacin12$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$337$64,69246 claims
Bausch & Lomb Americas Inc.Xiidra$163$25,89819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →